1. US FDA. Bioavailability studies submitted in NDAs or INDs – general considerations 2019 [Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-studies-submitted-ndas-or-inds-general-considerations.
2. CDER. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system guidance for industry 2017 [Available from: https://www.fda.gov/media/70963/download.
3. Agency EM. ICH Topic Q 1 D bracketing and matrixing designs for stability testing of drug substances and drug products 2002 [Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-d-bracketing-matrixing-designs-stability-testing-drug-substances-drug-products-step-5_en.pdf.
4. Pharmaceutical and food safety bureau . “Guideline for bioequivalence studies for formulation changes of oral solid dosage forms” English translation of Attachment 3 of Division-Notification 0229 No. 10 of the Pharmaceutical and Food Safety Bureau. Dated 2012; February 29. 2012 [Available from: https://www.nihs.go.jp/drug/be-guide(e)/form/GL-E_120229_shohou.pdf.
5. USFDA. SUPAC-IR: Immediate-release solid oral dosage forms: scale-up and post-approval changes: Chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. 1995.